This process is a potent immune modulating strategy for autoimmune diseases.[7, 28] Indeed, DC treated with AE/M displayed a tolerogenic phenotype and concurrently presented the self‐antigen MOG, leading to the establishment of MOG‐specific immune tolerance (Figure 7B–D). The gene discussed is MOG; the disease is autoimmune disease.